Mainz Biomed B.V.
MYNZ
$-0.14
Change (1 day)
$7.95
Year High
$0.18
Year Low
Categories
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
P/S ratio for Mainz Biomed B.V. (MYNZ)
P/S ratio as of 2023: 21.04
According to Mainz Biomed B.V.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 21.04. At the end of 2022 the company had a P/S ratio of 189.70.
P/S ratio history for Mainz Biomed B.V. from 2019 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 21.04 |
| 2022 | 189.70 |
| 2021 | 129.77 |
| 2020 | 113.49 |
| 2019 | 415.73 |